Lung Cancer Trials Advance EGFR-Testing Hypothesis for Iressa and Tarceva, Though Questions Remain

According to an editorial in the New England Journal of Medicine, two new studies suggest "that EGFR mutations represent favorable prognostic markers of survival and are predictive of tumor shrinkage, but the evidence that they can predict a differential effect of tyrosine kinase inhibitors on survival is incomplete."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.